share_log

Jefferies Downgrades Third Harmonic Bio to Hold, Lowers Price Target to $3.6

Benzinga Real-time News ·  Dec 16, 2022 06:02

Jefferies analyst Akash Tewari downgrades Third Harmonic Bio (NASDAQ:THRD) from Buy to Hold and lowers the price target from $30 to $3.6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment